Skip to main content

Advertisement

Table 1 Characteristics of 5 lung transplant recipients patients with posttransplant lymphoproliferative disorder (PTLD).

From: Post-transplant lymphoproliferative disorders and Epstein-Barr virus DNAemia in a cohort of lung transplant recipients

Pt. #, age, sex Underlying disease Date of TX Type of TX Onset of PTLD Immuno suppressive
treatment (dosage)
PTLD description EBV DNA copies/105PBMC
1, 29, M cystic fibrosis Dec. 2000 double-lung May 2003 Ciclosporin (350 mg/die)
Steroid (5 mg/die)
Laterocervical HL 1,760
2, 25, F cystic fibrosis Sep. 2001 double-lung May 2002 Ciclosporin (150 mg/die)
Steroid (40 mg/die)
Mediastinic large B-cells NHL < 10
3, 53, M sarcoidosis Dec. 2001 single-lung Nov. 2002 Ciclosporin (250 mg/die)
Steroid (25 mg/die)
Mediastinic large B-cells NHL < 10
4, 39, M Istiocytosis X Dec. 2004 double-lung May 2005 Ciclosporin (550 mg/die)
Steroid (5 mg/die)
thoracic localization of EBV-positive B-cell lymphoma. 307
5, 63, M Idiopathic pulmonary fibrosis Aug. 2006 double-lung Dec. 2006 Ciclosporin (300 mg/die)
Steroid (20 mg/die)
Mycophenolate mofetil (1000 mg/die)
Single nodule in lower left lobe, double mediastinic nodule (at histology, no tumor markers)
751,000 EBV DNA copies/μg tissue DNA, 8,500,000 copies/ml BAL
15, 289
  1. TX: transplantation; PBMC: peripheral blood mononuclear cells; M: male; F: female; HL: Hodgkin lymphoma; NHL: non-Hodgkin lymphoma.